Jing-Zhi Wang

Jing-Zhi Wang

Auto-generated profile, based on publicly available information

Jing-Zhi Wang

School of Atmospheric Sciences Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) Sun Yat‐Sen University Zhuhai China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2021 in Oncology Reports
Verified
Journal Article
Open access
PDF file
ZZZidi Zhou
Zidi Zhou
ZYZhilong Yang
Zhilong Yang
JWJingzhi Wang
Jingzhi Wang
QWQiang Wang
Qiang Wang
HZHeng Zhang
Heng Zhang
XJXiaoli Ju
Xiaoli Ju
Tumour‑associated macrophages (TAMs) are immune cells that are present in large numbers in the tumour immune microenvironment. TAMs are important for the occurrence, development, invasion, metastasis and immune escape of tumours. TAMs have become a novel therapeutic target and prognostic indicator in the individualised treatment of patients. Studies have reported that the number of TAMs can predict the size, stage and metastasis of gastric cancer. Therefore, in‑depth examination of TAMs may be important for high‑risk screening, early diagnosis and prognostic judgment of patients with gastric cancer. The present review examined the research progress of TAMs in gastric cancer on the basis of previous literature studies. Moreover, this review systematically evaluated the three major aspects of the differentiation of macrophages, the tumour‑promoting mechanism of TAMs in gastric cancer and the relationship between TAMs and treatment of gastric cancer. Finally, this review aimed to provide a reference for investigating the prognostic indicators and treatment targets of patients with gastric cancer.

19 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SLSining Liu
Sining Liu
XLXueyi Luo
Xueyi Luo
XZXiao-hui Zhang
Xiao-hui Zhang
LXLanping Xu
Lanping Xu
YWYu Wang
Yu Wang
XMXiao-Dong Mo
Xiao-Dong Mo
Relapse was the major cause of treatment failure in patients with acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify the efficacy and safety of preemptive interferon-α (IFN-α) treatment in ALL patients who had minimal residual disease (MRD) after allo-HSCT. Multiparameter flow cytometry and polymerase chain reaction assays were applied for MRD monitoring. Recombinant human IFN-α-2b injections were administered subcutaneously twice weekly in every 4 weeks cycle. Twenty-four (35.3%), 5 (7.4%), 6 (8.8%), and 13 (19.1%) patients achieved MRD negativity at 1, 2, 3, and > 3 months, respectively, after treatment. Seven patients showed grade ≥ 3 toxicities after IFN-α treatment. The 4-year cumulative incidence of total acute graft-versus-host disease (aGVHD), severe aGVHD, total chronic GVHD (cGVHD), and severe cGVHD after treatment was 14.7%, 2.9%, 40.0%, and 7.5%, respectively. The 4-year cumulative incidences of relapse and non-relapse mortality after treatment was 31.9% and 6.0%, respectively. The 4-year probabilities of disease-free survival and overall survival after IFN-α treatment were 62.1% and 71.1%, respectively. Thus, preemptive IFN-α treatment could protect against relapse and improve long-term survival for ALL patients who had MRD after allo-HSCT. The study was registered athttps://clinicaltrials.govas #NCT02185261 (09/07/2014).

16 December 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
Peng ZhaoPeng Zhao
Peng Zhao
YWYe-Jun Wu
Ye-Jun Wu
YHYun He
Yun He
SCShan Chong
Shan Chong
QQQing-Yuan Qu
Qing-Yuan Qu
XZXiao-hui Zhang
Xiao-hui Zhang
Transplant-associated thrombotic microangiopathy (TA-TMA) is a potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Information on markers for early prognostication remains limited, and no predictive tools for TA-TMA are available. We attempted to develop and validate a prognostic model for TA-TMA. A total of 507 patients who developed TA-TMA following allo-HSCT were retrospectively identified and separated into a derivation cohort and a validation cohort, according to the time of transplantation, to perform external temporal validation. Patient age (odds ratio [OR], 2.371; 95% confidence interval [CI], 1.264-4.445), anemia (OR, 2.836; 95% CI, 1.566-5.138), severe thrombocytopenia (OR, 3.871; 95% CI, 2.156-6.950), elevated total bilirubin (OR, 2.716; 95% CI, 1.489-4.955), and proteinuria (OR, 2.289; 95% CI, 1.257-4.168) were identified as independent prognostic factors for the 6-month outcome of TA-TMA. A risk score model termed BATAP (Bilirubin, Age, Thrombocytopenia, Anemia, Proteinuria) was constructed according to the regression coefficients. The validated c-statistic was 0.816 (95%, CI, 0.766-0.867) and 0.756 (95% CI, 0.696-0.817) for the internal and external validation, respectively. Calibration plots indicated that the model-predicted probabilities correlated well with the actual observed frequencies. This predictive model may facilitate the prognostication of TA-TMA and contribute to the early identification of high-risk patients.

1 May 2013 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
XMXiao-Dong Mo
Xiao-Dong Mo
LXLan-Ping Xu
Lan-Ping Xu
DLDai-hong Liu
Dai-hong Liu
XZXiao-hui Zhang
Xiao-hui Zhang
HCHuan Chen
Huan Chen
Xiaojun HuangXiaojun Huang
Xiaojun Huang
Human leukocyte antigen (HLA) partially matched related donor (PMRD) hematopoietic stem cell transplantation (HSCT) is an effective option for hematological malignancies. In this study, the nonmalignant late effects of PMRD HSCT were evaluated and compared with HLA-identical sibling donor (ISD) HSCT. Three hundred thirteen patients (ISD, n = 160; PMRD, n = 153) who survived at least 6 months and received regular follow-up examinations after their HSCT were enrolled. The 5-year cumulative incidence (±SE) of at least one late effect and multiple late effects was 47.30% ± .17% versus 58.21% ± .16% (P = .134) and 17.97% ± .10% versus 34.28% ± .15% (P = .001) for PMRD HSCT recipients versus ISD HSCT recipients, respectively. The cumulative incidence of keratoconjunctivitis sicca, periodontitis, ankylosis, myalgia, and nephrotic syndrome was lower among PMRD HSCT recipients compared with ISD HSCT recipients. Severe chronic graft-versus-host disease, multiple pre-HSCT chemotherapy cycles, female donor, and older age were risk factors for at least one late effect. Female donor, older age, and long-term immunosuppressive therapy were associated with multiple late effects. In summary, PMRD HSCT recipients have a lower risk of late effects compared with ISD HSCT recipients, possibly due to differences in protocols for graft-versus-host disease prophylaxis, and long-term follow-up after transplantation is recommended.


27 September 2023 in Nanoscale
Verified
Journal Article
Closed access
PDF file
JWJingzhi Wang
Jingzhi Wang
MLMei Li
Mei Li
ZJZhiliang Jin
Zhiliang Jin
Dynamics and morphology play a crucial role in the field of photocatalytic hydrogen production. Regulating the transfer of photogenerated charges is an effective way to improve the catalytic activity. In this paper, 1T-WS2 is introduced into a p–n heterostructure, ZnCdS/NiV-LDH, as a metalloid electron pump to transfer photogenerated electrons from semiconductors with larger work functions to metalloid materials with smaller work functions, effectively to attract photogenerated electrons, and promote charge rearrangement at the p–n heterostructure interface, so as to achieve the best utilization efficiency of photogenerated charges. Second, adjusting the morphology to increase the light absorption area of the catalyst is also a way to improve the photocatalytic activity. Two different nanosheet structures dispersed heavily stacked ZnCdS, increasing the light absorption area of the system. The optimal catalyst ratio achieves a hydrogen evolution rate of 22.37 mmol g−1 h−1, achieving 7.98% AQE and 2.12% STH conversion efficiency at 450 nm. The potential mechanism was demonstrated through in situ XPS. This study provides new insights into adding “electron pumps” to heterostructures to enhance photocatalytic activity.